Assess whether pediatric studies are necessary or waivable (7f1572)

Situation

After a pediatric ethicist objecting to the proposed design, RWE protocol that may not meet regulator expectations is what CMC change-control owner can touch in a rare-disease team designing a pediatric plan. Pharma & Life Sciences will live with Pediatric studies are necessary versus Waivable on this CMC and Development Pathways file.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose Pediatric studies are necessary / Waivable using RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• A pediatric ethicist objecting to the proposed design is noise around an already-controlled CMC and Development Pathways process in a rare-disease team designing a pediatric plan, given RWE protocol that may not meet regulator expectations.
• A pediatric ethicist objecting to the proposed design is the event in RWE protocol that may not meet regulator expectations that forces Pediatric studies are necessary for CMC change-control owner under Pharma & Life Sciences.
• RWE protocol that may not meet regulator expectations shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a CMC and Development Pathways program failure.
• RWE protocol that may not meet regulator expectations cannot decide pediatric studies are necessary yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close a rare-disease team designing a pediatric plan can defend.

Analysis required

• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a pediatric ethicist objecting to the proposed design and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation